GLP-1RA and SGLTi Therapy for Type 1 Diabetes
Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 300 (estimated)
- Sponsor
- Indiana University · Other
This trial is looking for adults with Type 1 Diabetes who have been prescribed certain medications as part of their care. Participants will be monitored for one year to see how these treatments work alongside insulin.
You may be able to join if
- I am at least 18 years old.
- I have been diagnosed with Type 1 Diabetes.
- I have been prescribed GLP-1RA or SGLTi for no more than 1 week.
- I use continuous glucose monitoring (CGM) and have CGM data from the past month.
- I am willing and able to provide informed consent.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThis will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.
Loading trial locations…